O	0	3	The
O	4	11	Natural
O	12	19	History
O	20	22	of
O	23	26	the
O	27	38	Progression
O	39	41	of
B-Symptom	42	49	Atrophy
O	50	59	Secondary
O	60	62	to
B-Disease	63	72	Stargardt
I-Disease	73	80	Disease
O	81	82	(
O	82	90	ProgStar
O	90	91	)
O	92	99	Studies
O	99	100	:
O	101	107	Design
O	108	111	and
O	112	120	Baseline
O	121	136	Characteristics
O	136	137	:
O	138	146	ProgStar
O	147	153	Report
O	154	156	No
O	156	157	.
O	158	159	1
O	159	160	.

O	162	164	To
O	165	173	describe
O	174	177	the
O	178	184	design
O	185	188	and
O	189	197	baseline
O	198	213	characteristics
O	214	216	of
O	217	225	patients
O	226	234	enrolled
O	235	239	into
O	240	241	2
O	242	249	natural
O	250	257	history
O	258	265	studies
O	266	268	of
B-Disease	269	278	Stargardt
I-Disease	279	286	disease
O	287	288	(
B-Disease	288	293	STGD1
O	293	294	)
O	294	295	.

O	296	307	Multicenter
O	308	321	retrospective
O	322	325	and
O	326	337	prospective
O	338	344	cohort
O	345	352	studies
O	352	353	.

O	354	359	Three
O	360	367	hundred
O	368	373	sixty
O	373	374	-
O	374	378	five
O	379	385	unique
O	386	394	patients
B-Characteristic	395	399	aged
I-Characteristic	400	401	6
I-Characteristic	402	407	years
I-Characteristic	408	411	and
I-Characteristic	412	417	older
O	418	420	at
O	421	429	baseline
O	430	439	harboring
B-Characteristic	440	447	disease
I-Characteristic	447	448	-
I-Characteristic	448	455	causing
I-Characteristic	456	464	variants
I-Characteristic	465	467	in
I-Characteristic	468	471	the
I-Characteristic	472	477	ABCA4
I-Characteristic	478	482	gene
O	483	486	and
O	487	491	with
O	492	501	specified
B-Symptom	502	508	ocular
I-Symptom	509	516	lesions
O	517	521	were
O	522	530	enrolled
O	531	535	from
O	536	537	9
O	538	545	centers
O	546	548	in
O	549	552	the
B-Characteristic	553	559	United
I-Characteristic	560	566	States
O	567	570	and
B-Characteristic	571	577	Europe
O	577	578	.

O	579	581	In
O	582	585	the
O	586	599	retrospective
O	600	605	study
O	605	606	,
O	607	615	patients
O	616	627	contributed
B-Diagnostic_tool	628	635	medical
I-Diagnostic_tool	636	642	record
I-Diagnostic_tool	643	647	data
O	648	652	from
O	653	655	at
O	656	661	least
O	662	663	2
O	664	667	and
O	668	670	up
O	671	673	to
O	674	675	4
O	676	682	visits
O	683	686	for
O	687	689	at
O	690	695	least
O	696	697	1
O	698	709	examination
O	710	718	modality
O	718	719	:
B-Diagnostic_tool	720	726	fundus
I-Diagnostic_tool	727	743	autofluorescence
O	744	745	(
B-Diagnostic_tool	745	748	FAF
O	748	749	)
O	749	750	,
B-Diagnostic_tool	751	759	spectral
I-Diagnostic_tool	759	760	-
I-Diagnostic_tool	760	766	domain
I-Diagnostic_tool	767	768	(
I-Diagnostic_tool	768	770	SD
I-Diagnostic_tool	770	771	)
I-Diagnostic_tool	772	779	optical
I-Diagnostic_tool	780	789	coherence
I-Diagnostic_tool	790	800	tomography
O	801	802	(
B-Diagnostic_tool	802	804	SD
I-Diagnostic_tool	805	808	OCT
O	808	809	)
O	809	810	,
O	811	814	and
O	814	815	/
O	815	817	or
B-Diagnostic_tool	818	832	microperimetry
O	833	834	(
B-Diagnostic_tool	834	836	MP
O	836	837	)
O	837	838	.

O	839	842	The
O	843	848	total
O	849	862	observational
O	863	869	period
O	870	873	was
O	874	876	at
O	877	882	least
O	883	884	2
O	885	890	years
O	891	894	and
O	895	897	up
O	898	900	to
O	901	902	5
O	903	908	years
O	909	916	between
O	917	923	single
O	924	930	visits
O	930	931	.

B-Characteristic	932	943	Demographic
O	944	947	and
B-Characteristic	948	954	visual
I-Characteristic	955	961	acuity
O	962	963	(
B-Characteristic	963	965	VA
O	965	966	)
O	967	971	data
O	972	976	also
O	977	981	were
O	982	990	obtained
O	990	991	.

O	992	994	In
O	995	998	the
O	999	1010	prospective
O	1011	1016	study
O	1016	1017	,
O	1018	1026	eligible
O	1027	1035	patients
O	1036	1040	were
O	1041	1049	examined
O	1050	1052	at
O	1053	1061	baseline
O	1062	1067	using
O	1068	1069	a
O	1070	1078	standard
O	1079	1087	protocol
O	1087	1088	,
O	1089	1093	with
O	1094	1095	6
O	1095	1096	-
O	1096	1101	month
O	1102	1108	follow
O	1108	1109	-
O	1109	1111	up
O	1112	1118	visits
O	1119	1126	planned
O	1127	1130	for
O	1131	1132	a
O	1133	1134	2
O	1134	1135	-
O	1135	1139	year
O	1140	1146	period
O	1147	1150	for
O	1151	1157	serial
B-Diagnostic_tool	1158	1163	Early
I-Diagnostic_tool	1164	1173	Treatment
I-Diagnostic_tool	1174	1182	Diabetic
I-Diagnostic_tool	1183	1194	Retinopathy
I-Diagnostic_tool	1195	1200	Study
I-Diagnostic_tool	1201	1202	(
I-Diagnostic_tool	1202	1207	ETDRS
I-Diagnostic_tool	1207	1208	)
I-Diagnostic_tool	1209	1213	best
I-Diagnostic_tool	1213	1214	-
I-Diagnostic_tool	1214	1223	corrected
I-Diagnostic_tool	1224	1226	VA
O	1226	1227	,
B-Diagnostic_tool	1228	1230	SD
I-Diagnostic_tool	1231	1234	OCT
O	1234	1235	,
B-Diagnostic_tool	1236	1239	FAF
O	1239	1240	,
O	1241	1244	and
B-Diagnostic_tool	1245	1247	MP
O	1247	1248	.

O	1249	1255	Design
O	1256	1259	and
O	1260	1269	rationale
O	1270	1272	of
O	1273	1274	a
O	1275	1286	multicenter
O	1287	1292	study
O	1293	1295	to
O	1296	1305	determine
O	1306	1309	the
O	1310	1321	progression
O	1322	1324	of
B-Disease	1325	1330	STGD1
O	1331	1333	in
O	1334	1335	2
O	1336	1341	large
O	1342	1355	retrospective
O	1356	1359	and
O	1360	1371	prospective
O	1372	1385	international
O	1386	1393	cohorts
O	1393	1394	.

O	1395	1403	Detailed
O	1404	1412	baseline
O	1413	1428	characteristics
O	1429	1431	of
O	1432	1436	both
O	1437	1444	cohorts
O	1445	1448	are
O	1449	1458	presented
O	1458	1459	,
O	1460	1469	including
B-Characteristic	1470	1482	demographics
O	1482	1483	,
O	1484	1487	and
B-Characteristic	1488	1498	structural
I-Characteristic	1499	1502	and
I-Characteristic	1503	1513	functional
I-Characteristic	1514	1521	retinal
I-Characteristic	1522	1529	metrics
O	1529	1530	.

O	1531	1535	Into
O	1536	1539	the
O	1540	1553	retrospective
O	1554	1559	study
O	1559	1560	,
O	1561	1564	251
O	1565	1573	patients
O	1574	1575	(
O	1575	1578	458
B-Anatomy	1579	1583	eyes
O	1583	1584	)
O	1585	1589	were
O	1590	1598	enrolled
O	1598	1599	;
O	1600	1604	mean
O	1605	1611	follow
O	1611	1612	-
O	1612	1614	up
O	1615	1616	±
O	1617	1625	standard
O	1626	1635	deviation
O	1636	1639	was
O	1640	1641	3
O	1641	1642	.
O	1642	1643	9
O	1643	1644	±
O	1644	1645	1
O	1645	1646	.
O	1646	1647	6
O	1648	1653	years
O	1653	1654	.

O	1655	1657	At
O	1658	1666	baseline
O	1666	1667	,
O	1668	1670	36
O	1670	1671	%
O	1672	1675	had
O	1676	1678	no
O	1679	1681	or
B-Symptom	1682	1686	mild
I-Symptom	1687	1689	VA
I-Symptom	1690	1694	loss
O	1694	1695	,
O	1696	1699	and
O	1700	1702	47
O	1702	1703	%
O	1704	1706	of
O	1707	1710	the
O	1711	1716	study
B-Anatomy	1717	1721	eyes
O	1722	1725	had
O	1726	1731	areas
O	1732	1734	of
B-Symptom	1735	1745	definitely
I-Symptom	1746	1755	decreased
I-Symptom	1756	1772	autofluorescence
O	1773	1774	(
B-Symptom	1774	1778	DDAF
O	1778	1779	)
O	1780	1784	with
O	1785	1787	an
O	1788	1795	average
O	1796	1802	lesion
O	1803	1807	area
O	1808	1810	of
B-Dimension	1811	1812	2
I-Dimension	1812	1813	.
I-Dimension	1813	1814	5
I-Dimension	1814	1815	±
I-Dimension	1815	1816	2
I-Dimension	1816	1817	.
I-Dimension	1817	1818	9
I-Dimension	1819	1821	mm
I-Dimension	1821	1822	(
I-Dimension	1822	1823	2
I-Dimension	1823	1824	)
O	1825	1826	(
O	1826	1831	range
O	1831	1832	,
O	1833	1834	0
O	1834	1835	.
O	1835	1837	02
O	1837	1838	-
O	1838	1840	16
O	1840	1841	.
O	1841	1843	03
O	1844	1846	mm
O	1846	1847	(
O	1847	1848	2
O	1848	1849	)
O	1849	1850	)
O	1850	1851	.

O	1852	1855	Two
O	1856	1863	hundred
O	1864	1869	fifty
O	1869	1870	-
O	1870	1874	nine
O	1875	1883	patients
O	1884	1885	(
O	1885	1888	489
B-Anatomy	1889	1893	eyes
O	1893	1894	)
O	1895	1899	were
O	1900	1908	enrolled
O	1909	1911	in
O	1912	1915	the
O	1916	1927	prospective
O	1928	1933	study
O	1933	1934	.

O	1935	1937	At
O	1938	1946	baseline
O	1946	1947	,
O	1948	1950	20
O	1950	1951	%
O	1952	1955	had
B-Symptom	1956	1958	no
I-Symptom	1959	1961	or
I-Symptom	1962	1966	mild
I-Symptom	1967	1969	VA
I-Symptom	1970	1974	loss
O	1974	1975	,
O	1976	1979	and
O	1980	1982	64
O	1982	1983	%
O	1984	1987	had
O	1988	1993	areas
O	1994	1996	of
B-Symptom	1997	2001	DDAF
O	2002	2006	with
O	2007	2009	an
O	2010	2017	average
O	2018	2024	lesion
O	2025	2029	area
O	2030	2032	of
B-Dimension	2033	2034	4
I-Dimension	2034	2035	.
I-Dimension	2035	2036	0
I-Dimension	2036	2037	±
I-Dimension	2037	2038	4
I-Dimension	2038	2039	.
I-Dimension	2039	2040	4
I-Dimension	2041	2043	mm
I-Dimension	2043	2044	(
I-Dimension	2044	2045	2
I-Dimension	2045	2046	)
O	2047	2048	(
O	2048	2053	range
O	2053	2054	,
O	2055	2056	0
O	2056	2057	.
O	2057	2059	03
O	2059	2060	-
O	2060	2062	24
O	2062	2063	.
O	2063	2065	24
O	2066	2068	mm
O	2068	2069	(
O	2069	2070	2
O	2070	2071	)
O	2071	2072	)
O	2072	2073	.

O	2074	2077	The
B-Characteristic	2078	2082	mean
I-Characteristic	2083	2090	retinal
I-Characteristic	2091	2102	sensitivity
O	2103	2107	with
B-Diagnostic_tool	2108	2110	MP
O	2111	2114	was
B-Dimension	2115	2117	10
I-Dimension	2117	2118	.
I-Dimension	2118	2119	8
I-Dimension	2119	2120	±
I-Dimension	2120	2121	5
I-Dimension	2121	2122	.
I-Dimension	2122	2123	0
I-Dimension	2124	2126	dB
O	2126	2127	.

O	2128	2131	The
O	2132	2140	ProgStar
O	2141	2148	cohorts
O	2149	2153	have
O	2154	2162	baseline
O	2163	2178	characteristics
O	2179	2183	that
O	2184	2193	encompass
O	2194	2195	a
O	2196	2200	wide
O	2201	2206	range
O	2207	2209	of
O	2210	2217	disease
O	2218	2226	severity
O	2227	2230	and
O	2231	2234	are
O	2235	2243	expected
O	2244	2246	to
O	2247	2254	provide
O	2255	2263	valuable
O	2264	2268	data
O	2269	2271	on
O	2272	2283	progression
O	2284	2289	based
O	2290	2292	on
O	2293	2299	serial
O	2300	2312	quantitative
O	2313	2325	measurements
O	2326	2333	derived
O	2334	2338	from
O	2339	2347	multiple
O	2348	2355	methods
O	2355	2356	,
O	2357	2362	which
O	2363	2367	will
O	2368	2370	be
O	2371	2379	critical
O	2380	2382	to
O	2383	2386	the
O	2387	2393	design
O	2394	2396	of
O	2397	2404	planned
O	2405	2413	clinical
O	2414	2420	trials
O	2420	2421	.
